Fireside Chat, Interview, Conference Presentation
How Angela Hwang helped lead Pfizer through the unknowns of Covid to deliver a vaccine
- Humanity may sustain the speed and collaboration seen during Project Lightspeed in non-crisis periods, though achieving this without high-stakes emergency pressure is expected to be significantly more difficult.
- There is a risk that Pfizer will revert to pre-pandemic operating habits, resulting in reduced experimentation and less frequent failure cycles.
- The company faces the potential inability to consistently activate parallel pathing capabilities in future development cycles, a strategy identified as critical for innovation.
- Angela Huang plans to maintain long-term investment in diversity and representation, noting that building a sufficient talent bench and community will require years.
- A collective progress strategy will be implemented wherein every individual executes one specific action intended to evolve into subsequent initiatives.
- A cultural shift toward leader vulnerability, including admitting to daily decision changes, is expected to be translated into everyday behavior beyond the crisis context.
- Future innovation efforts will rely on delineating immovable areas like patient safety and FDA submissions from remaining operational areas deemed adaptable.